search for


J Korean Med Rehabi 2019 Jan; 29(1): 75-83  
Clinical Study on Child’s Height Growth of Mixtures of Cynanchum wilfordii and Phlomis umbrosa Extract
Published online January 31, 2019
Copyright © 2019 The Society of Korean Medicine Rehabilitation.

Ki Chan Ha, Ph.D.*, Hyang Im Baek, Ph.D.*, Hye Mi Kim, M.S.*, Young Mi Kim, B.S.*, Da Young Jeong, B.S.*, Seong Je Hong, B.S., Sang Keun Hong, B.S., Chang Min Choi, K.M.D., Ph.D.

Healthcare Claims and Management Incorporated*, Panaxan Corporation, Department of Gynecology of Korean Medicine, College of Korean Medicine, Wonkwang University
Correspondence to: Chang-Min Choi, Department of Gynecology of Korean Medicine, Gwangju Medical Center, Wonkwang University, 1140-23 Hoejae-ro, Nam-gu, Gwangju 61729, Korea TEL (062) 670-6437 FAX (062) 670-6767 E-mail
Received: December 21, 2018; Revised: January 7, 2019; Accepted: January 8, 2019
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objectives Previous animal studies have shown that mixtures of Cynanchum wilfordii and Phlomis umbrosa extract (IPLUS-CWPU) increases femur length and insulin like growth factor- 1 (IGF-1) secretion. IPLUS-CWPU may thus be a promising ingredient in functional foods aimed at growing child's height. The purpose of the study is to investigate the effect of IPLUS-CWPU on height growth in children with short stature.
Methods For this purpose, we recruited 90 children aged 4 to 12 years who had heights ranging from the 5th to 25th percentiles of Korean children's growth curve and randomized to either the IPLUS-CWPU or the placebo group.
Results The IPLUS-CWPU group showed a significant increase in the change of the height growth compared to the placebo group after 20 weeks of administration (p=0.02). The height growth velosity also showed a statistically significant difference in the test group compared to the placebo group at 10 weeks (p=0.04). The IGF-1 levels showed a tendency to increase in the IPLUS-CWPU group (p=0.08). Moreover, the IPLUS-CWPU significantly increased IGF-1/IGFBP-3 ratio (p=0.02). However, there were no significant differences in blood biochemical parameters including growth hormone, bone age, thyroid stimulating hormone, and osteocalcin levels.
Conclusions In conclusion, the data of this trial indicate that IPLUS-CWPU is effective and safe, generally well-tolerated without severe adverse events, in the treatment of children with short stature over a 20 weeks period.
Keywords : Growth, Short stature, Insulin like growth factor-1 (IGF-1), Growth hormone

January 2019, 29 (1)

Cited By Articles
  • CrossRef (0)

  • Crossref TDM
  • CrossMark
  • orcid